The Filing Desk

NRX Pharmaceuticals vs Rani Therapeutics

NRX Pharmaceuticals NRXP · Rani Therapeutics RANI · Pharmaceuticals

Rani Therapeutics reported revenue of $2 million in fiscal 2025, 1.3 times NRX Pharmaceuticals' $1 million in fiscal 2025. NRX Pharmaceuticals had an operating margin of -1324.4%, against -2346.0% at Rani Therapeutics.

Side by side

NRX PharmaceuticalsRani Therapeutics
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$2M
Revenue growth—58.9%
Revenue growth a year, last 5 years—26.2%
Gross margin58.8%—
Operating margin−1,324.4%−2,346.0%
Net margin−2,336.5%−1,817.1%
Free cash flow—−$19M
Free cash flow margin—−1,151.4%
Return on capital—−127.1%
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count101.1%132.3%
Last close$2.55$0.58
P/E at the last close——
Insider trades, last 12 months—bought $50,040, sold $301
Piotroski F-score—4 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
NRX PharmaceuticalsRani Therapeutics
Operating margin
Percent of revenue
NRX PharmaceuticalsRani Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
NRX PharmaceuticalsRani Therapeutics

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the NRX Pharmaceuticals and Rani Therapeutics pages.